Fludarabine phosphate and Adenoviral haemorrhagic cystitis - a phase IV clinical study of FDA data

Summary:

Adenoviral haemorrhagic cystitis is reported as a side effect among people who take Fludarabine phosphate (fludarabine phosphate), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Tacrolimus, and have Bone marrow conditioning regimen.

The phase IV clinical study analyzes which people have Adenoviral haemorrhagic cystitis when taking Fludarabine phosphate. It is created by eHealthMe based on reports of 12,833 people who have side effects when taking Fludarabine phosphate from the FDA, and is updated regularly.

What is Fludarabine phosphate?

Fludarabine phosphate has active ingredients of fludarabine phosphate. eHealthMe is studying from 12,840 Fludarabine phosphate users. Check the latest studies of Fludarabine phosphate.

What is Adenoviral haemorrhagic cystitis?

Adenoviral haemorrhagic cystitis is found to be associated with 32 drugs and 127 conditions by eHealthMe. Check the latest studies of Adenoviral haemorrhagic cystitis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

12,833 people reported to have side effects when taking Fludarabine phosphate.
Among them, 30 people (0.23%) have Adenoviral haemorrhagic cystitis.

Could Fludarabine phosphate cause Adenoviral haemorrhagic cystitis?

Among these 30 people:

How long have people been on Fludarabine phosphate when they have Adenoviral haemorrhagic cystitis? *

What is the gender of people who have Adenoviral haemorrhagic cystitis when taking Fludarabine phosphate? *

female: 39.29 %
male: 60.71 %

What is the age of people who have Adenoviral haemorrhagic cystitis when taking Fludarabine phosphate? *

What are other drugs people take besides Fludarabine phosphate? *

Tacrolimus: 16 people, 53.33%
Methotrexate: 10 people, 33.33%
Cyclophosphamide: 10 people, 33.33%
Busulfex: 9 people, 30.00%
Cyclosporine: 8 people, 26.67%
Cytarabine: 6 people, 20.00%
Prednisolone: 6 people, 20.00%
Neupogen: 4 people, 13.33%
Heparin: 3 people, 10.00%
Methylprednisolone Sodium Succinate: 3 people, 10.00%

What are other side effects people have besides Adenoviral haemorrhagic cystitis? *

Acute Graft Versus Host Disease In Intestine (acute complication in intestine following an allogeneic tissue/blood transplant): 7 people, 23.33%
Engraftment Syndrome (inflammatory condition during neutrophil recovery after hematopoietic stem cell transplantation): 7 people, 23.33%
Herpes Zoster: 7 people, 23.33%
Haematuria (presence of blood in urine): 6 people, 20.00%
Urination - Painful: 6 people, 20.00%
Acute Graft Versus Host Disease (acute complication following an allogeneic tissue/blood transplant): 6 people, 20.00%
Stomatitis (inflammation of mucous membrane of mouth): 6 people, 20.00%
Nausea (feeling of having an urge to vomit): 6 people, 20.00%
Malaise (a feeling of general discomfort or uneasiness): 5 people, 16.67%
Cytomegalovirus Viraemia (cytomegalo virus in blood stream): 5 people, 16.67%

What are the existing conditions these people have? *

Bone Marrow Conditioning Regimen: 13 people, 43.33%
Aplastic Anemia: 3 people, 10.00%
Sepsis (a severe blood infection that can lead to organ failure and death): 2 people, 6.67%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 2 people, 6.67%
Weakness: 1 person, 3.33%
Thymoma (a tumour originating from the epithelial cells of the thymus): 1 person, 3.33%
Rectal Ulcer (ulcer of rectum): 1 person, 3.33%
Post Transplant Lymphoproliferative Disorder: 1 person, 3.33%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 1 person, 3.33%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 1 person, 3.33%

* Approximation only. Some reports may have incomplete information.

Do you take Fludarabine phosphate and have Adenoviral haemorrhagic cystitis?

- Check whether Adenoviral haemorrhagic cystitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Fludarabine phosphate:

Fludarabine phosphate (12,840 reports)

Browse all side effects of Fludarabine phosphate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Adenoviral haemorrhagic cystitis:

Adenoviral haemorrhagic cystitis (32 drugs)

Browse all the conditions that are associated with Adenoviral haemorrhagic cystitis:

Adenoviral haemorrhagic cystitis (127 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fludarabine phosphate (the active ingredients of Fludarabine phosphate) and Fludarabine phosphate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.